Abstract
Type II endoleak after endovascular aortic aneurysm repair (EVAR) is common (8%-44%). Interventions for type II endoleak have had a technical success rate of >80%. However, the clinical success rates, defined as aneurysm sac stabilization or shrinkage, have been significantly lower. The aim of this study was to assess the technical success, safety, and clinical benefit of AneuFix (TripleMed, Geleen, The Netherlands), a novel polymer-based material that is directly injected into the aneurysm sac in patients with a type II endoleak and a growing aneurysm.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
